Declaration of Conformity and Annex 4 Label, AE and FSCA Declarations

1. Key takeaways

A Singapore registration submission carries a set of declarations rather than a single one: the declaration of conformity under GN-11 R1.3, the letter of authorisation in Annex 1, the marketing history declaration in Annex 2, the safety declaration in Annex 3, and the label, AE and FSCA declaration in Annex 4, which GN-15 R14 introduced with effect from 14 September 2026. Annex 4 has two parts with different reach. Part 1 requires applicants filing through the Abridged, Expedited or Immediate route to disclose differences between the Singapore label and the label approved by the reference agency. Part 2 requires every applicant, without exception, to disclose the history of reportable adverse events and field safety corrective actions.

• The declaration set is cumulative. Each document answers a different question, and none of them can stand in for another.
• GN-15 R15 of October 2026 is the current registration guidance; Annex 4 entered through R14, effective 14 September 2026.
• Annex 4 Part 1 applies to the Abridged, Expedited and Immediate routes and concerns label differences against the reference agency approval.
• Annex 4 Part 2 applies to all applications and concerns adverse event and field safety corrective action history.
• The declaration of conformity under GN-11 R1.3 is a self-declaration, but a false one carries legal consequences in Singapore.

2. Legal basis

GN-15 governs product registration and supplies the annex templates that accompany an application. The current revision is R15 of October 2026, and the annexes in use are Annex 1 (letter of authorisation), Annex 2 (marketing history declaration), Annex 3 (safety declaration) and Annex 4 (label, AE and FSCA declaration), all dated October 2026. The declaration of conformity sits outside that series and is governed separately by GN-11 R1.3, Guidance on the Declaration of Conformity, of November 2022, together with the GN-11 DoC template of the same date. The two instruments serve different purposes: GN-11 records conformity with the Essential Principles and the standards relied on, while the GN-15 annexes record the administrative and historical facts on which the route qualification depends.

The division of labour between the documents is set out below. Reading them as a package matters, because the same fact often appears in two of them, and the reviewer compares the answers.

Regulatory information in this article was verified to 26 October 2026. The GN-15 R15 annexes and GN-11 R1.3 were checked against secondary sources; the specific provisions introduced by R14 rest on an industry compilation of the amendment and should be confirmed against the official HSA text before filing.

3. Expert insights

Annex 4 turns safety history from a reactive answer into a proactive filing. This is the most operationally significant change of 2026. Before R14, historical recalls and vigilance records were generally produced when HSA asked for them. After R14, every application has to disclose that history at the point of submission. A product with a recall in another jurisdiction now has to explain it in the file, at the time of filing, whether or not anyone would have thought to ask. The change shifts the drafting burden forward, and it also shifts the risk: an undisclosed event that surfaces later is a different category of problem from an event disclosed and explained.

Annex 2 is the direct evidence for the Immediate route. Condition A of the Class B Immediate route requires not less than three years of marketing history in the jurisdiction concerned. Annex 2 is the vehicle that carries that evidence. When we argue Immediate route eligibility we ask the client to list the first marketing date for each jurisdiction separately, then cross-check those dates against the reference agency approval dates. A consolidated statement that the product has been sold for several years is not sufficient, because the condition is jurisdiction-specific and the reviewer will test it that way.

Annex 3 and the safety conditions of the Immediate route come from the same source. The Immediate route requires no safety issues, no deaths, no open field safety corrective action and no rejected applications. The Annex 3 safety declaration is the written form of that same set of conditions. There is no room for optimism when completing it, because the declaration is read against the Part 2 disclosure in Annex 4. The two documents corroborate each other, and an inconsistency between them is visible on the face of the file rather than buried in it.

The Part 1 label comparison is, in substance, a self-audit of the reliance basis. HSA relies on the reference agency’s assessment, and that reliance assumes the product is the same. Requiring the applicant to disclose label differences is a way of making the applicant run the eligibility question first. If the differences are substantial, the route qualification may not hold at all. It is far better to discover that by comparison than to have it discovered at review, which is why we treat the comparison as a decision point: adjust the label, or change the route.

The declaration of conformity is self-declared but not informal. The DoC under GN-11 R1.3 is the Product Owner’s own statement, and it is easy to treat as paperwork. It is not. A false declaration engages liability under Singapore law, and the statement is filed as part of the regulatory record. In our projects the DoC is signed by a person with actual authority to bind the company, and the supporting evidence behind each declared standard is listed so that the statement can be defended if it is ever tested.

4. Practical recommendations

• Prepare the four annex declarations and the DoC as a single exercise, since they corroborate one another and drafting them separately is how contradictions appear.
• List marketing history jurisdiction by jurisdiction, with verifiable evidence of the first launch date for each.
• Request adverse event and FSCA history from the manufacturer early, as it is required for Annex 4 Part 2 and is the one input the Registrant does not hold.
• Run the label comparison first and decide consciously whether to adjust the label or change the route if the differences are substantial.
• Keep a supporting evidence list behind every declaration, so that the statements can be defended if HSA queries them.

5. Verification checklist

• □ DoC issued on the GN-11 R1.3 template and signed by an authorised person.
• □ Annex 1 letter of authorisation signed.
• □ Annex 2 marketing history listed by jurisdiction with supporting evidence.
• □ Annex 3 safety declaration issued.
• □ Annex 4 Part 1 label differences disclosed, where the Abridged, Expedited or Immediate route applies.
• □ Annex 4 Part 2 adverse event and FSCA history disclosed, for all applications.
• □ Content consistent across all declarations.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com